Get notified of page updates

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

Olaparib for Metastatic Breast Cancer without a gBRCA Mutation

Clinicaltrials.gov identifier:
NCT03344965
PRINTER FRIENDLY PAGE
Overview
Who Can Join
Glossary on
off

 About the Study

This study is no longer recruiting people. 

DFCI 17-428 ( Expanded) is a study looking at whether the drug is effective treatment for people with certain types of breast cancer.  belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited mutation. This study is looking at whether is also effective for treating breast cancer in people who do not have an inherited mutation.

 

This Study is Open To:

This study is no longer recruiting people. 

This Study is NOT Open To:

This study is no longer recruiting people. 

Clinicaltrials.gov identifier:
NCT03344965
PRINTER FRIENDLY PAGE